Delivery Order SPE2DB22D2103-SPE2DB25FR9UG
- Not listed
- The Defense Logistics Agency awarded a $8,118.08 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ibrance 125 mg capsules (21-count packages). The contract, with a completion date of September 30, 2025, represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $40,612.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count packaging) with an ultimate completion date of September 30, 2025. This competitive award, issued on September 9, 2025, carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count) on August 29, 2025, with completion expected by September 22, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,122.48 on August 12, 2025, for the supply of Ibrance 100 mg tablets (7-unit package). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count package) on August 1, 2025, with an ultimate completion date of August 22, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ibrance 100 mg capsules (21-count packaging) at a ceiling value of $8,122.48 under a firm fixed-price contract. This is a non-set-aside competitive award with a completion date of September 2, 2025, and represents a child contract under AmerisourceBergen's larger contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for Ibrance 125 mg capsules (21-count) on August 13, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $24,367.44 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count package) on August 27, 2025, with an ultimate completion date of September 18, 2025. This competitive award uses firm fixed pricing and carries no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in that...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ibrance 125 mg capsules (21-count units). The award is a firm fixed price contract with an ultimate completion date of October 2, 2025, and was competitively awarded with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count) on August 19, 2025, with completion targeted for September 10, 2025. The contract utilizes firm fixed pricing and was competitively awarded without a set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location....
- SPE2DB22D2103Indefinite Delivery Contract
- SPE2DB22D2103-SPE2DB25FR9UGDelivery Order
The Defense Logistics Agency awarded a $40,609.48 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ibrance 100 mg capsules (quantity 21s), with an ultimate completion date of October 2, 2025. This non-set-aside contract is to be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, maintains a substantial federal contract portfolio with the Defense Logistics Agency, supplying a comprehensive range of pharmaceuticals and medical supplies to military and veteran healthcare systems. The company's established Indefinite Delivery Contract enables flexible delivery orders for various pharmaceutical products across multiple therapeutic domains to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This specific delivery order for Ibrance—an oncology medication—exemplifies the company's role as a critical vendor within the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $40.6k | 9/11/25 |